Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K M Radomski

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Annals of Pharmacotherapy|February 1, 1997
Assay interaction between oxaprozin and phenytoinT Patel, K M Radomski, M H Chandler
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 1, 1997
General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patientsK M Radomski, G A Davis, M H Chandler
The Annals of Pharmacotherapy|March 13, 1998
Collaboration between pharmacy and laboratory: defining total allowable error limits for therapeutically monitored drugsK M Radomski, B A Bush, M H Ensom
Antimicrobial Agents and Chemotherapy|July 18, 2000
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjectsS Weller, K M Radomski, Y Lou, et al.
Anti-Cancer Drugs|October 17, 1998
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patientsM A Socinski, P N Mudd, K M Radomski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecanM K Ma, W C Zamboni, K M Radomski, et al.
Leukemia|October 6, 2000
Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effectsM K Arnaout, K M Radomski, D K Srivastava, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Annals of Pharmacotherapy|February 1, 1997
Assay interaction between oxaprozin and phenytoinT Patel, K M Radomski, M H Chandler
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 1, 1997
General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patientsK M Radomski, G A Davis, M H Chandler
The Annals of Pharmacotherapy|March 13, 1998
Collaboration between pharmacy and laboratory: defining total allowable error limits for therapeutically monitored drugsK M Radomski, B A Bush, M H Ensom
Antimicrobial Agents and Chemotherapy|July 18, 2000
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjectsS Weller, K M Radomski, Y Lou, et al.
Anti-Cancer Drugs|October 17, 1998
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patientsM A Socinski, P N Mudd, K M Radomski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecanM K Ma, W C Zamboni, K M Radomski, et al.
Leukemia|October 6, 2000
Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effectsM K Arnaout, K M Radomski, D K Srivastava, et al.
Pageof 1